

FOR IMMEDIATE RELEASE

CONTACT INFORMATION
Jack Minster
DSG, Inc.
+1 (484) 913-2112
jminster@dsg-us.com



SUPERNUMS PHARMACEUTICALS SELECTS DSG, INC. FOR EDC AND IWRS IN PHASE 3 CLINICAL STUDIES ON IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS TREATED FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)

MALVERN, Pa., April 1, 2016 —[DSG](#), a leader in electronic data capture (EDC), was selected by [Supernus Pharmaceuticals](#), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, to provide a fully supported [eCaseLink](#) EDC system, including [IWRS](#) Web-based Randomization-Clinical Supply, a Central lab and third-party CRO data integration, and data management services for two blinded Phase 3 clinical studies on impulsive aggression in pediatric patients being treated for Attention Deficit/Hyperactivity Disorder (ADHD). Leveraging pieces of DSG’s eCaseLink system (EDC and IWRS) will allow Supernus to significantly reduce clinical trial time, reduce trial cost, improve trial accuracy, and overall provide a more effective clinical trial with greater impact.

A truly integrated solution, [DSG’s eCaseLink](#) seamlessly combines EDC, [ePRO](#), Risk-Based Monitoring, [eSource](#), [IWRS Randomization-Clinical Supply](#), [Drug Safety](#), Site Payments and [CTMS](#) into a single harmonized system. DSG’s clinical [study build tool](#) makes initial EDC startup intuitive and fast, with unparalleled support services and hands-on training for self-build studies, used also by DSG’s team in providing full service SaaS software systems.

“DSG is extremely proud that Supernus has chosen the eCaseLink suite,” said Tony Varano, CEO of DSG. “We look forward to helping Supernus advance the treatment of central nervous system diseases through the use of embedded and transformational applications. This is further evidence that our eClinical solutions are not only leading from a technology perspective, but that our people, processes and product delivery remain the most highly trusted in the industry.”

[eCaseLink IWRS](#), an integrated component of the EDC software, allows Supernus to manage randomization, subject enrollment, and drug supply in their clinical trial. DSG is managing all aspects of clinical study data management from database setup through lock. DSG's data management team adds value to their EDC service by providing Supernus with clean, timely, and cost-effective deliverables throughout the lifespan of the study. With 25 years of clinical trial software and service experience, DSG expertly provides the development and design of customized databases, design and review of eCRFs, data validation programming, comprehensive data management plans, ongoing review of data and logic checks, local laboratory Normals maintenance, data management, data encoding, reconciliation of serious adverse events, and database lock, submission and archiving.

About DSG

[DSG, Inc.](#) supports clinical data capture and management with a proprietary, organically integrated suite of award-winning user-friendly technology solutions, including flagship eCaseLink™ EDC, Risk-Based Monitoring, eSource, ePRO, IWRS Randomization-Clinical Supply Systems, Drug Safety System, and CTMS. Since 1992, DSG has successfully supported thousands of clinical trials for over 400 companies and 25,000 sites across 93 countries, headquartered in Malvern, Pa., with additional offices in the U.S. and Asia: www.dsg-us.com.

About Supernus

[Supernus Pharmaceuticals, Inc.](#) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in ADHD patients. SPN-812 is being developed for treatment of ADHD.

###

All products and services above are the property of their respective owners.